Briefcase Email Alerts Downloads Snapshot RSS Email Printed Materials Print this page

Achieve

Download Library


 
Download Library
Date Document Type
  View Presentation
  View Presentation
  Amended and Restated Bylaws
2016 2015 Annual Report
Annual Reports
2016 2015 Letter to Shareholders
Annual Reports
  View Presentation
  RG-101 in Combination with 4 Weeks of Oral Direct Acting Antiviral Therapy Achieves High Virologic Response Rates in Treatment Na├»ve Genotype 1 and 4 Chronic Hepatitis C Patients: Interim Results from a Randomised, Multi-Center, Phase 2 Study
Apr 14, 2016 A single dose with anti-miR122 oligonucleotide RG-101 results in a less activated phenotype of NK cells in patients with chronic hepatitis C
Apr 14, 2016 RG-101 DEMONSTRATES FAVORABLE IN VITRO ANTIVIRAL ACTIVITY AND CROSS RESISTANCE PROFILE TO SUPPORT CLINICAL COMBINATION STUDIES IN HCV PATIENTS
Apr 14, 2016 Sequence Analysis for Resistance Monitoring Following a Single Dose of RG-101, an anti-miR Targeting microRNA-122, in Chronic Hepatitis C Patients
Page:
1
NextLast
= add file to Briefcase